Sandoz AG

Sandoz has resolved its Hatch-Waxman patent-infringement dispute with AbbVie in the US over the originator’s Rinvoq (upadacitinib) extended-release tablets, declaring that its proposed abbreviated new

After Sandoz several years ago lost US patent litigation with Amgen over Enbrel (etanercept) – preventing Sandoz from launching its Erelzi (etanercept-szzs) version until 2029 – the firm is now tryi

Spain’s competition authority, the CNMC, has announced that it is investigating Sandoz and its Bexal subsidiary – as well as other companies Alliance Healthcare España and Bluetab Solutions – over the

The end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D